MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort.
MiR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort.
复制标题
DOI:
10.1038/emm.2014.81
复制
发表时间:
2015-02-06
影响因子:
12.8
通讯作者:
Luo, Shanshun
中科院分区:
文献类型:
--
作者:
Han, Hui;Qu, Guangjin;Han, Chenghua;Wang, Yuhong;Sun, Tingting;Li, Fengqing;Wang, Junxiao;Luo, Shanshun
The aim of this study was to investigate the expression of circulating microRNAs (miRNAs) in apolipoprotein E (apoE) knockout mice (apoE−/−) and to validate the role of these miRNAs in human coronary artery disease (CAD). Pooled plasma from 10 apoE−/− mice and 10 healthy C57BL/6 (B6) mice was used to perform the microarray analysis. The results showed that miR-34a, miR-21, miR-23a, miR-30a and miR-106b were differentially expressed in apoE−/− mice, and these expression changes were confirmed by real-time quantitative reverse-transcription PCR. Then, miR-34a, miR-21, miR-23a, miR-30a and miR-106b were detected in the plasma of 32 patients with CAD and of 20 healthy controls. Only miR-34a, miR-21 and miR-23a were significantly differentially expressed in the plasma of CAD patients (all P<0.01). In conclusion, miR-34a, miR-21 and miR-23a were elevated in CAD patients, which means that these miRNAs might serve as biomarkers of CAD development and progression.
登录
查看更多内容
影响因子:
64.8
作者:
He, Lin;He, Xingyue;Hannon, Gregory J.
通讯作者:
Hannon, Gregory J.
影响因子:
18.2
作者:
Dickinson, Brent A.;Semus, Hillary M.;van Rooij, Eva
通讯作者:
van Rooij, Eva
影响因子:
14.9
作者:
Griffiths-Jones, Sam;Saini, Harpreet Kaur;van Dongen, Stijn;Enright, Anton J.
通讯作者:
Enright, Anton J.
影响因子:
3.7
作者:
Gilad S;Meiri E;Yogev Y;Benjamin S;Lebanony D;Yerushalmi N;Benjamin H;Kushnir M;Cholakh H;Melamed N;Bentwich Z;Hod M;Goren Y;Chajut A
通讯作者:
Chajut A
DOI:
10.1161/01.atv.0000036081.01231.16
发表时间:
2002-11-01
影响因子:
8.7
作者:
Bea, F;Blessing, E;Rosenfeld, ME
通讯作者:
Rosenfeld, ME